Q3 Biotech Roundup: The 2024 Turnaround Sputters into a Critical Q4 Finale

Q3 biotech roundup: The 2024 turnaround sputters into a critical Q4 finale

In Q3 2024, despite mixed indicators for biotech business activity, DealForma’s numbers show that the industry is on track to surpass 2023’s deal totals, though a strong finish in Q4 will be crucial for exceeding last year’s licensing upfronts. Check out Endpoints report.

All of this by stage, disease indication, modality, target…

+ 0 k
Licensing Deals
+ 0 k
M&A
+ 0 k
Other Deals
+ 0 k
Funding Rounds
+ 0 k
Company Profiles
+ 0 k
Drug Sales Figures